New therapies for the treatment of heart failure with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35524990/
doi: 10.1093/ajhp/zxac129. Online ahead of print. 1 South University School of Pharmacy, Savannah, GA, and St. Joseph's/Candler Health System, Savannah, GA, USA. 2 St. Joseph's/Candler Health System, Savannah, GA, USA....
Conclusion: The PARAGON-HF and EMPEROR-Preserved trials will serve as the foundation for a new era in the treatment of HFpEF.
Share
Healthcare resource utilization and associated costs | CEOR
In Germany, the current estimates of the prevalence of diabetes range between 7.2% (population aged 18 to 79 years) based on health examination surveys of the Robert Koch Institute and...
Conclusion: Although the individual clinical patient profile and physician assessment are paramount in treatment decisions, substantial differences in the economic impact of different antidiabetic therapies should be considered.
Share
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35501824/
Empagliflozin showed some positive effects in 4 cases with better renal function than CKD stage 4. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors...
Conclusion: Empagliflozin showed some positive effects in 4 cases with better renal function than CKD stage 4. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors in a larger group of patients with similar medical conditions.
Share
-
Heart Failure Connect3yrKey Points • Source: BMC Nephrology • Conclusion: “Empagliflozin showed some positive effects in 4 cases with better renal function than CKD [chronic kidney disease] stage 4. Further studies will Show More
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35510595/
Solid clinical data support the current recommendations to use empagliflozin or dapagliflozin in HFrEF. The underlying mechanisms likely include changes in cardiac and intrarenal haemodynamic. Yet, these mechanisms do not...
Conclusions: Solid clinical data support the current recommendations to use empagliflozin or dapagliflozin in HFrEF. The underlying mechanisms likely include changes in cardiac and intrarenal haemodynamic. Yet, these mechanisms do not seem to solely explain the observed magnitude of clinical effect with SGLT2 inhibitors in HFrEF and other...
Share
Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35512448/
doi: 10.1093/jpp/rgac022. Online ahead of print. 1 Department of Natural Products, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, Chunilal Bhawan 168, Maniktala Main Road, Kolkata, West Bengal, India....
Conclusion: There was a significant change in the AUC0-t and Cmax of ATR, ALO and EMPA after co-administration with Acai berry. Further studies are recommended to confirm the clinical significance of these interactions.
Share